PMID- 34124742
OWN - NLM
STAT- MEDLINE
DCOM- 20220106
LR  - 20220106
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 156
IP  - 6
DP  - 2021 Nov 8
TI  - Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 
      2018 ASCO/CAP Clinical Practice Guidelines.
PG  - 1130-1141
LID - 10.1093/ajcp/aqab083 [doi]
AB  - OBJECTIVES: To examine and compare human epidermal growth factor receptor 2 
      (HER2) amplification status in high-grade urothelial carcinoma (HGUCa), using 
      both 2013 and 2018 HER2 reporting guidelines for breast carcinoma from the 
      American Society of Clinical Oncology (ASCO)/College of American Pathologists 
      (CAP). METHODS: HER2 status by fluorescence in situ hybridization (FISH) assay in 
      78 cases of HGUCa was compared using 2013 and 2018 HER2 reporting guidelines. 
      RESULTS: HER2 amplification was observed in 22 (28.2%) of 78 tumors, of which 17 
      were in group 1, 1 in group 2, and 2 each in groups 3 and 4 (FISH assay, 2018). 
      The remaining 14 HER2-amplified tumors (FISH assay, 2013) became negative, 
      falling into group 2 (FISH assay, 2018) and were either negative or equivocal on 
      immunohistochemistry (IHC, 2018). All FISH-negative tumors (n = 37) using 2013 
      criteria remained negative (group 5, 2018). FISH-equivocal tumors (2013) were 
      further categorized into HER2 amplified (n = 1) and HER2 negative (n = 4) (2018). 
      Overall, 20 (25.6%) tumors had discordant HER2 FISH results (2018 vs 2013). 
      CONCLUSIONS: Implementing 2018 guidelines, HER2 amplification decreased from 36 
      to 22 cases. The group with a HER2/CEP17 ratio of 2 or more and average HER2 copy 
      number less than 4 (group 2) were predominantly negative by IHC, suggesting a 
      biologically distinct group of HGUCa that is different from HER2-amplified 
      tumors, which may not respond to HER2-targeted therapy.
CI  - (c) American Society for Clinical Pathology, 2021. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Mohanty, Sambit K
AU  - Mohanty SK
AD  - Department of Pathology and Laboratory Medicine, Advanced Medical Research 
      Institute, Bhubaneswar, India.
AD  - Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, 
      India.
FAU - Mishra, Sourav K
AU  - Mishra SK
AD  - Department of Medical Oncology, Advanced Medical Research Institute, Bhubaneswar, 
      India.
FAU - Tiwari, Ankit
AU  - Tiwari A
AD  - Department of Pathology and Laboratory Medicine, Advanced Medical Research 
      Institute, Bhubaneswar, India.
FAU - Sharma, Shivani
AU  - Sharma S
AD  - Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, 
      India.
FAU - Bhardwaj, Mohit
AU  - Bhardwaj M
AD  - Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, 
      India.
FAU - Pattnaik, Niharika
AU  - Pattnaik N
AD  - Department of Pathology and Laboratory Medicine, Advanced Medical Research 
      Institute, Bhubaneswar, India.
FAU - Jaiswal, Sunil
AU  - Jaiswal S
AD  - Department of Surgical Oncology, Advanced Medical Research Institute, 
      Bhubaneswar, India.
FAU - Baisakh, Manas R
AU  - Baisakh MR
AD  - Department of Pathology and Laboratory Medicine, Prolife Diagnostics, 
      Bhubaneswar, India.
FAU - Das, Subodh
AU  - Das S
AD  - Department of Urology, Advanced Medical Research Institute, Bhubaneswar, India.
FAU - Pradhan, Manas R
AU  - Pradhan MR
AD  - Department of Urology, Advanced Medical Research Institute, Bhubaneswar, India.
FAU - Swain, Tapas R
AU  - Swain TR
AD  - Department of Pathology and Laboratory Medicine, Advanced Medical Research 
      Institute, Bhubaneswar, India.
FAU - Satpathy, Kaliprasad
AU  - Satpathy K
AD  - Department of Urology, Kalinga Hospital, Bhubaneswar, India.
FAU - Williamson, Sean R
AU  - Williamson SR
AUID- ORCID: 0000-0002-3898-1460
AD  - Department of Pathology, Cleveland Clinic , Cleveland, OH, USA.
FAU - Parwani, Anil V
AU  - Parwani AV
AD  - Department of Pathology, Wexner Medical Center, Ohio State University, Columbus, 
      OH, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Breast Neoplasms
MH  - *Carcinoma, Transitional Cell
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Practice Guidelines as Topic
MH  - Receptor, ErbB-2/genetics
MH  - *Urinary Bladder Neoplasms
OTO - NOTNLM
OT  - ASCO/CAP practice guidelines
OT  - FISH
OT  - HER2
OT  - High-grade bladder cancer
EDAT- 2021/06/15 06:00
MHDA- 2022/01/07 06:00
CRDT- 2021/06/14 10:00
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2022/01/07 06:00 [medline]
PHST- 2021/06/14 10:00 [entrez]
AID - 6298214 [pii]
AID - 10.1093/ajcp/aqab083 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2021 Nov 8;156(6):1130-1141. doi: 10.1093/ajcp/aqab083.